-The Indian Express When the Delhi Development Authority had the sole right to build houses in the capital, it was unable to meet the demand from an expanding population. If private builders stepped in to build where the DDA was not doing so, is it a fair calculation to say that the profit they could make was a loss to the government exchequer? The CAG’s estimate of loss to the government...
More »SEARCH RESULT
Total Matching Records found : 864
Farm production needs to rise 60 % by 2050: UN agency
—AFP World farm production must rise 60 per cent by 2050 to meet the needs of a growing population but this has to happen in a “more sustainable way”, the U.N. food agency FAO and the OECD said on Wednesday. “It’s mostly going to be about productivity”, said Angel Gurria, head of the Organisation for Economic Cooperation and Development (OECD), at a press conference in Rome, explaining that farmland area would increase...
More »‘Only auction’ approach not correct, AG tells court-J Venkatesan
-The Hindu Auction alone cannot be insisted upon for disposal of all types of natural resources, Attorney General (AG) G.E. Vahanvati asserted in the Supreme Court on Thursday. Such an approach mandated in the 2G judgment, apart from being impractical in certain situations, can be counter-productive and can impact planned and coordinated growth and economy of the country, the AG told a five-judge Constitution Bench comprising Chief Justice S.H. Kapadia and Justices...
More »The perils of retail therapy in India
-Live Mint There is no dearth of advisors for a government considered to be in the grip of a policy paralysis and whose prime minister is dubbed an “underachiever”. In this season of India-bashing, US President Barack Obama spared some time from his election campaign and offered some pearly words of wisdom on the Indian economy. This came at a time when in his own backyard, thousands of people marched in...
More »Natco targets drugs ripe for compulsory licensing-Viswanath Pilla
-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...
More »
